4
Total investments
1
Early stage
0
Mid stage
0
Late stage
16y
Years active
Portfolio
4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Dec 2024
We are building the future of modular, open-source architectures supporting the Department of Defense requirements to create Affordable Mass. Firestorm is redefining military expectations for on-site modularity to support the widest array of mission areas.
Investor and Strategic Advisor
Oct 2024
Point Zenith is a client centred consultancy and service provider. Unlocking technological capabilities through regulatory advancement, personnel training, and concept development to enable business growth and mission success.
Investor
Aug 2024
Were an AI research company that builds reliable, interpretable, and steerable AI systems. Our first product is Claude, an AI assistant for tasks at any scale.
Our research interests span multiple areas including natural language, human feedback, scaling laws, reinforcement learning, code generation, and interpretability.
Experience · 9 entries
All (9)
Investments (4)
Founder (1)
2024
Investor
Dec 2024
We are building the future of modular, open-source architectures supporting the Department of Defense requirements to create Affordable Mass. Firestorm is redefining military expectations for on-site modularity to support the widest array of mission areas.
Strategic Advisor
Nov 2024
Hageman Capital provides upfront capital to real estate development projects through the purchase of single-site, developer-backed, Tax Increment Financing (TIF) Bonds.
Investor and Strategic Advisor
Oct 2024
Point Zenith is a client centred consultancy and service provider. Unlocking technological capabilities through regulatory advancement, personnel training, and concept development to enable business growth and mission success.
Strstegic Advisor to the President and CEO
Sep 2024
We focus on venture creation of biotechnology and pharmaceutical drug discovery & development companies. Our philosophy is based on the fundamentals of venture creation and due diligence to launch relatively mature and vetted start-up companies. We build value with experienced executives and drug development teams, focused scientific and development milestones, active advisors, and a virtual or quasi-virtual business model for capital efficiency.
Portfolio companies: Gate Neurosciences, Anagin, other stealth mental health focused companies in progress; Assembly Pharmaceuticals (now Assembly Biosciences, Nasdaq: ASMB); Assembly China, Naurex (Acquired by Allergan), Aptinyx (Nasdaq: APTX; Naurex spin out); Coferon/Blink Bio, others not disclosed.
Investor
Aug 2024
Were an AI research company that builds reliable, interpretable, and steerable AI systems. Our first product is Claude, an AI assistant for tasks at any scale.
Our research interests span multiple areas including natural language, human feedback, scaling laws, reinforcement learning, code generation, and interpretability.
Show all 9 entries ↓
Investment activity
2010–2024 · 4 investments
Recent (last 2 years)Earlier
